The Current Role of Bone Marrow Transplantation in the Treatment of Hemophilia A

Bone marrow transplantation (BMT) is nowadays used in various hematological disorders including leukemias. Hemophilia A is sex linked bleeding disorder in which there are various genetic abnormalities in factor VIII gene. Among various hematological disorders, bleeding disorders mainly hemophilia in now widely treated using plasma derived and recombinant factor VIII concentrates. Day to day transfusion of coagulation factor VIII in current lifelong disorder is a burden for the patients and decreases their quality of life. Although infection of coagulation products with blood-borne viruses that was major concern in treatment of hemophilia has been eliminated nearly complete at the present time, but appearance of factor VIII inhibitor is huge burden in treatment of hemophilia for both clinicians and patients. In this day and age BMT has gathered new insight and acceptable treatment for many hematological and non-hematological disorders. If BMT will be successful in treatment of hemophilia, it will improve quality of life (by nearly permanent treatment without necessary of daily treatment) and decrease mortality rate (by providing continuous coagulation factor level in blood system). The aim of current review was to determine current role of BMT in treatment of hemophilia and to evaluate current usage of BMT for treatment of hemophilia. The review of literatures showed that although BMT has been used in a rare cases with hemophilia (mainly hemophilia with another blood disorder), it does not use commonly in treatment of patients with hemophilia A at present time. Literature review showed that scientists now focused on bone marrow transplantation in animal model of hemophilia.